Patents by Inventor Claudie Madoulet

Claudie Madoulet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
    Patent number: 8409580
    Abstract: The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies. The invention relates to said composition for defining means for treating multidrug resistances.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: April 2, 2013
    Assignee: AC Immune SA
    Inventors: Pierre-Francois Tosi, Claudie Madoulet, Claude Nicolau, David T. Hickman
  • Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
    Patent number: 7807171
    Abstract: The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies. The invention relates to said composition for defining means for treating multidrug resistances.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: October 5, 2010
    Assignee: AC Immune SA
    Inventors: Pierre-Francois Tosi, Claudie Madoulet, Claude Nicolau, David T. Hickman
  • THERAPEUTIC VACCINE TARGETED AGAINST P-GLYCOPROTEIN 170 FOR INHIBITING MULTIDRUG RESISTANCE IN THE TREATMENT OF CANCERS
    Publication number: 20080026995
    Abstract: The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human use and is coupled at its free end to a phospholipids, e.g., phosphatidylethanolamine or any other chemically suitable phospholipid.
    Type: Application
    Filed: October 18, 2006
    Publication date: January 31, 2008
    Applicant: AC IMMUNE SA
    Inventors: Pierre-Francois Tosi, Claudie Madoulet, Yves-Claude Nicolau, David T. Hickman
  • Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
    Publication number: 20060233758
    Abstract: The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human use and is coupled at its free end to a phospholipids, e.g., phosphatidylethanolamine or any other chemically suitable phospholipid.
    Type: Application
    Filed: November 16, 2005
    Publication date: October 19, 2006
    Inventors: Pierre-Francois Tosi, Claudie Madoulet, Claude Nicolau, David Hickman
  • Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
    Publication number: 20050255561
    Abstract: The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human use and is coupled at its free end to a phospholipids, e.g., phosphatidylethanolamine or any other chemically suitable phospholipid.
    Type: Application
    Filed: February 16, 2005
    Publication date: November 17, 2005
    Inventors: Pierre-Francois Tosi, Claudie Madoulet, Claude Nicolau, David Hickman